摘要
目的 探讨P33^(INGI)表达在胰腺癌的发生、发展中的生物学特征和临床意义。方法 选取胰腺癌、癌旁组织与胰腺良性病变标本,应用组织芯片(又称组织微阵列)技术和免疫组化方法研究P33^(INGI)、P53和MDM2在胰腺良恶性病变中的表达情况。结果 P33^(INGI)在胰腺癌与癌旁组织中表达的阳性率分别为77.2％(129/167)、60.4％(61/101)。P33^(INGI)的阳性表达与肿瘤的分化和神经受累显著相关(P<0.05);P53的阳性表达与肿瘤的分化、淋巴结转移和神经受累均显著相关(P<O.05);MDM2的阳性表达与肿瘤的分化显著相关(P<0.05)。胰腺癌组织中P33^(INGI)与P53、MDM2的表达均呈正相关。结论 P33^(INGI)在胰腺癌的发生发展中可能起重要作用,P33^(INGI)与P53及MDM2的联合表达与胰腺癌的临床生物学行为有关。
Objective To investigate the pathological relationship between P33 ING1 expression and pancreatic carcinoma and clinical significance. Methods Pathological specimens from 167 pancreatic carcinomas, 101 paracancerous non-tumor pancreatic tissues and 18 pancreatic benign lesions were examined for P33ING1, P53 and MDM2 proteins by tissue microarray technique and immunohistochemistry. Results P33 ING1 expression in pancreatic carcinoma and paracancerous non-tumor tissues was 77. 2%(129/167) and 60. 4%(61/101), respectively. P33ING1 expression in pancreatic carcinoma was significantly related to tumor differentiation and nerve infiltration (P<0. 05). P53 expression was significantly related to tumor differentiation, lymph node metastasis and nerve infiltration (P<0. 05). MDM2 expression was significantly related to tumor differentiation (P< 0.05). There was a positive correlation of P33ING1 expression with P53 and MDM2 (P<0. 05, P< 0. 01) in pancreatic carcinoma. Conclusions P33ING1 may play an important role in the development and progression of pancreatic carcinoma. Coexpression of P33ING1 and P53 and MDM2 is related to the clinical biological behavior of pancreatic carcinoma.
出处
《胰腺病学》
2002年第4期199-203,共5页
Chinese JOurnal of Pancreatology
基金
长海医院"258"学科建设计划资助
